DDInter228 DDInter1491
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide (Compound) resembles Pomalidomide (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Pomalidomide (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pomalidomide (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)